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Progressive supranuclear palsy (PSP) is a rare movement disorder and often difficult to distinguish
clinically from Parkinson’s disease (PD) and multiple system atrophy (MSA) in early phases. In
this study, we report reproducible disease-related topographies of brain network and regional
glucose metabolism associated with PSP in clinically-confirmed independent cohorts of PSP, MSA
and PD patients and healthy controls in the USA and China. Using 18F-FDG PET images from
PSP and healthy subjects, we applied spatial covariance analysis with bootstrapping to identify a
PSP-related pattern (PSPRP) and estimate its reliability, and evaluated the ability of network
scores for differential diagnosis. We also detected regional metabolic differences using statistical
parametric mapping analysis. We produced a highly reliable PSPRP characterized by relative
metabolic decreases in the middle prefrontal cortex/cingulate, ventrolateral prefrontal cortex,
striatum, thalamus and midbrain, covarying with relative metabolic increases in the hippocampus,
insula and parieto-temporal regions. PSPRP network scores correlated positively with PSP
duration and accurately discriminated between healthy, PSP, MSA and PD groups in two separate
cohorts of parkinsonian patients at both early and advanced stages. Moreover, PSP patients shared
many overlapping areas with abnormal metabolism in the same cortical and subcortical regions as
in the PSPRP. With rigorous cross-validation, this study demonstrated highly comparable and
reproducible PSP-related metabolic topographies at network and regional levels across different
patient populations and PET scanners. Metabolic brain network activity may serve as a reliable
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and objective marker of PSP, although cross-validation applying recent diagnostic criteria and
classification is warranted.

Keywords
movement disorders; parkinsonism; differential diagnosis; PET; disease-related brain network
markers; multivariate and univariate brain mapping methods

Introduction

Author Manuscript

Progressive supranuclear palsy (PSP) is one of the most common forms of atypical
parkinsonism characterized by gait dysfunction, gaze palsy, cognitive impairment, early
dysphagia and dysarthria. At early disease stages, PSP remains difficult to diagnose because
of its substantial overlap of clinical symptoms with Parkinson’s disease (PD), multiple
system atrophy (MSA), corticobasal degeneration and dementia with Lewy bodies. Despite
progressive improvement in clinical diagnostic criteria for parkinsonian syndromes in the
past few decades, it has been reported that approximately 20-47% of patients with PSP are
still misdiagnosed in life (Joutsa et al., 2014; Respondek et al., 2013). Given that disease
prognoses and treatment options can differ considerably, a correct diagnosis of PSP from
other types of parkinsonism is of great importance in clinical practice as well as in research
trials of novel therapies.

Author Manuscript

Neuroimaging with positron emission tomography (PET) has been used extensively to
provide increased accuracy of clinical diagnosis for PSP in vivo. So far, reduced striatal
binding in dopaminergic imaging has demonstrated high sensitivity for detecting PSP and
other forms of parkinsonism, but it has not been sufficiently accurate for discrimination
among these diseases (Jin et al., 2013). Although cholinergic deficiency in cortical and
subcortical regions may be suggestive of PSP, this marker has shown neither sensitivity nor
specificity, especially at early stages of the disease (Gilman et al., 2010; Hirano et al., 2010).
The application of functional imaging of neuropathology (i.e., tau fibrillar aggregates and βamyloid deposition) is still in its infancy, thereby also being of limited value in early
differential diagnosis of parkinsonism (Broski et al., 2014; Kepe et al., 2013).

Author Manuscript

Brain metabolic activity measured with 18F-fluorodeoxyglucose (18F-FDG) PET has proven
to be valuable for studying parkinsonian disorders (Eckert et al., 2005; Eckert et al., 2008;
Niethammer and Eidelberg, 2012; Teune et al., 2010; Teune et al., 2013; Wu et al., 2013; Wu
et al., 2014). In the past decade, a variety of voxel-based techniques have been successfully
applied to 18F-FDG PET images to describe characteristic patterns of regional glucose
metabolism in patients with PSP. To date, disease-specific metabolic markers associated with
PSP have been reported in several independent patient cohorts to assist in early differential
diagnosis on a single-case basis. This prospective application was facilitated qualitatively by
visually inspecting the similarity of each 18F-FDG PET image to PSP-related metabolic
templates (Eckert et al., 2005; Teune et al., 2010) or quantitatively by assessing the activity
of PSP-related metabolic networks (Eckert et al., 2008; Teune et al., 2013). These studies
utilized two complementary (i.e., univariate or multivariate) analytical approaches but were
limited by the lack of objective comparisons between the patterns across independent
Hum Brain Mapp. Author manuscript; available in PMC 2019 July 01.
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imaging centers. Before the PSP-related metabolic marker can be used as a reference
standard to help routine clinical diagnosis, it is necessary to assess its reproducibility on a
whole-brain basis in a direct comparison of different patient cohorts using the same
analytical techniques.
In this study, we used multivariate brain network analysis to identify, characterize and crossvalidate PSP-related metabolic patterns (PSPRP) together and separately in an American
cohort and a comparable Chinese cohort of both healthy control subjects and patients with
parkinsonism. We also evaluated similarities and differences in abnormal regional
metabolism in these 18F-FDG PET images using univariate brain mapping analysis.
Moreover, we examined the reproducibility of PSP-specific metabolic characteristics and
network biomarkers across study populations, PET instruments and analytical approaches.

Author Manuscript

Material and Methods
Subjects

Author Manuscript

This study included two different cohorts of healthy subjects and parkinsonian patients. The
first cohort were recruited from both American and Chinese populations resulting in a total
of 100 participants: 20 normal controls along with 20 PSP, 20 MSA and 40 PD patients. The
American cohort was comprised of 10 healthy subjects and 10 PSP, 10 MSA and 20 PD
patients recruited at North Shore University Hospital (NY, USA) and used originally for the
identification and internal evaluation of disease-related metabolic patterns associated with
parkinsonism (i.e., PSPRP, MSARP and PDRP) (Eckert et al., 2008; Ma et al., 2007). These
patterns had played a critical role in the development and validation of novel classification
algorithms for early differential diagnosis of parkinsonism in independent populations from
different countries (Ko et al., 2017; Niethammer et al., 2014; Tang et al., 2010; Tripathi et
al., 2016). To match the sample size, the Chinese cohort consisted of the same numbers of
healthy subjects and parkinsonian patients who were prospectively enrolled at Huashan
Hospital (Shanghai, China) between Jan 2014 and Sept 2015. Demographic and clinical data
for the healthy and patient groups are provided in Table I. In the combined cohort there was
a trend effect of age among four subject groups (ANOVA: F[3,96] = 2.46, P = 0.067) with
the PSP patients marginally older than the healthy controls (P = 0.068). The patients with
PSP and MSA were highly similar in their clinical characteristics but had more severe motor
symptoms and shorter disease duration than the PD patients. These individuals underwent
18F-FDG PET imaging at the American and Chinese sites respectively.

Author Manuscript

Before taking part in this study, all patients were followed by two specialists of movement
disorders at each institution for at least one year. The clinical diagnosis was further
ascertained through post-imaging follow-up by the clinicians who were blinded to the
imaging results. All patients with PSP met the consensus diagnostic criteria for “probable”
PSP (NINDS-SPSP) (Hoglinger et al., 2017; Litvan et al., 1996; Respondek et al., 2013) and
showed vertical supranuclear palsy and prominent postural instability with tendency to fall
in the first year of disease onset. All patients with MSA and PD satisfied the criteria of the
Second Consensus Statement on the Diagnosis of MSA (Gilman et al., 2008) and the UK
Brain Bank (Gibb and Lees, 1988), respectively. These were clinically-confirmed patients at
relatively advanced stages in order to identify and cross-validate disease-specific patterns.
Hum Brain Mapp. Author manuscript; available in PMC 2019 July 01.
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However, most patients referred to scanning in clinical routine are more likely to be
suspected of having parkinsonism at earlier stages. To more realistically assess differential
diagnosis of parkinsonism we included a second independent Chinese cohort with a total of
68 participants: 20 normal controls and 14 PSP, 14 MSA and 20 PD patients (Table II).
These patients were initially scanned with FDG PET at the Chinese site as clinically
uncertain cases, and then followed up for several years until a clinical diagnosis was made
unequivocally by their neurologists. The subjects in this early patient cohort were at very
early clinical stages (P < 0.05) compared to those in the combined American and Chinese
cohort (Table I) with less severe motor symptoms (PSP: P = 0.33; MSA or PD: P < 0.005)
and shorter disease duration (P < 0.005). Normal control and PSP subjects were closed
matched in age (P ≥ 0.25) but MSA and PD patients were younger (P < 0.001) compared to
those in the combined cohort. No patients showed brain structural abnormalities (e.g. mass
lesions and ischemia) on magnetic resonance imaging (MRI). All healthy controls
participating in this study underwent a neurological examination by a senior movement
disorders specialist to rule out history of neurologic or psychiatric disorders. None of the
patients and healthy volunteer subjects had any prior exposure to neuroleptic agents or drug
use.

Author Manuscript

Ethical permission for the study procedures was obtained from the Institutional Review
Boards at North Shore University Hospital and Huashan Hospital. This study was done in
compliance with the Code of Ethics of the World Medical Association (Declaration of
Helsinki) and the standards established by the author’s local Institutional Review Boards and
granting agencies. Written consent was obtained at each institution from each subject
following detailed explanation of the scanning procedures. Authors had access to
information that could identify individual participants during or after data collection.

Author Manuscript

18F-FDG

PET Imaging

Author Manuscript

All subjects were asked to fast for at least 6 h but had free access to water prior to imaging.
All patients underwent 18F-FDG PET at least 12 h after the cessation of oral
antiparkinsonian medications. The American subjects were scanned on a GE Advance
Tomograph (General Electric, Milwaukee, WI) in three-dimensional (3D) mode (Ma et al.,
2007). Following a transmission scan, a PET scan was acquired over 35-45 min after an
intravenous injection of 18F-FDG (5-10 mCi) and reconstructed with the 3D reprojection
method. The Chinese subjects were scanned with a Siemens Biograph 64 PET/CT (Siemens,
Munich, Germany) in 3D mode (Wu et al., 2013). After a CT transmission scan for
attenuation correction, a PET scan was acquired over 45-55 min post-injection and
reconstructed with the ordered subset expectation maximization method. All studies in
patients and normal subjects were performed in a resting state in a quiet and dimly lit room.
Only relative brain glucose metabolism was measured without arterial blood sampling as in
any routine clinical imaging protocol.
Image Processing
PET images were preprocessed using Statistical Parametric Mapping software (SPM5;
Wellcome Department of Imaging Neuroscience, Institute of Neurology, London, UK)
implemented in Matlab 7.4.0 (MathworksInc, Sherborn, MA). Scans were spatially
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normalized into Montreal Neurological Institute (MNI) brain space with linear and nonlinear
3D transformations. They were then smoothed by a Gaussian filter of 10 mm width over a
3D space to increase signal to noise ratio for statistical analysis.
Network Analysis

Author Manuscript

Brain network analysis and related computing procedures were performed using ScanVP
software, Version 5.9.1 (http://www.feinsteinneuroscience.org at Center for Neuroscience,
the Feinstein Institute for Medical Research, Manhasset, NY). Disease-related brain network
was generated using 18F-FDG PET data from patients and healthy subjects by applying a
voxel-based spatial covariance mapping algorithm known as Scaled Subprofile Modeling
based on principal component analysis (SSM/PCA). This algorithm and procedures have
been described in detail previously (Ma et al., 2007; Spetsieris and Eidelberg, 2011). Briefly,
the method executed PCA on covariance matrix of group-wise image data within a brain
mask of gray matter for identifying a disease-related spatial covariance pattern with greater
expression in patients than in control subjects. The pattern was defined by a linear
combination of select principal components (PCs) whose expression could best discriminate
the patients from the controls, as determined by the lowest Akaike Information Criterion
(AIC) value in a logistical regression model. Subject scores of this pattern were computed
prospectively in any other scans using a voxel-based topographic profile rating (TPR)
algorithm. This entailed multiplying each individual image with that of the pattern (i.e., dot
product between the two images) and summing the result over the brain mask. The resulting
scores were then Z-transformed by using subject scores of the healthy controls involved in
the pattern identification, i.e., Z-score = (score – control mean)/control standard deviation.

Author Manuscript

Pattern identification and disease discrimination—Specific metabolic pattern
associated with PSP (PSPRP) were identified using 18F-FDG PET data from the PSP and
healthy subjects in the combined American and Chinese cohort. The reliability of this
pattern was estimated at each voxel by means of an iterative bootstrapping scheme (Habeck
et al., 2008; Peng et al., 2014). This step produced a map of inverse coefficient of variation
(ICV) to assess a brain-wide statistic. Network scores of PSPRP were then computed for all
scans in the combined cohort as well as in the early patient cohort and Z-scored using
subject scores of the healthy controls in the identification cohort of PSPRP.

Author Manuscript

Cross-validation of topographies and pattern expression between the USA
and China—We next identified a separate PSPRP using 18F-FDG PET scans of PSP and
healthy subjects in the American and Chinese cohorts respectively and quantitatively
evaluated their similarities in terms of topographic distribution and network expression. The
topographies were assessed by voxel-based correlation of regional weights in a set of
significant voxels over the whole brain. Only the voxels with absolute values ≥1.0 were used
to calculate the correlation between the two patterns. Subject scores of each pattern were
calculated for the normal, PSP, MSA and PD groups in each cohort and cross-validated by
computing network scores of the PSPRP identified in the USA for the subjects in China or
vice versa. Group discrimination was examined using the subject scores within each site and
across the two sites. Moreover, the subject scores for the PSPRP identified in the USA were
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also correlated with those for the prospective validation of the PSPRP derived in China or
vice versa.
Analysis of Regional Metabolic Activity

Author Manuscript

Differences in regional metabolism between patients and normal controls were analyzed
using SPM5 as described previously (Zuo et al., 2013). For the combined or separate cohort,
we used a two-sample t-test according to the general linear model to characterize metabolic
activity in PSP patients compared with controls. Mean signal differences over the whole
brain were modeled by ANCOVA per subject. The contrasts for the decreased and increased
metabolism were set as [1 −1] and [−1 1]. Using SPM5 we also utilized a flexible factorial
design to localize brain regions with common or different abnormal metabolism between the
American and Chinese cohorts (Asanuma et al., 2006), with site and group added as two
main effects and global values entered as a covariate to eliminate the potential confound.
The contrasts for the commonality and the differences were detected separately using
conjunction analysis [1, −1, 1, −1]/[ −1, 1, −1, 1] and interaction analysis [1, −1, −1, 1]/[−1,
1, 1, −1].

Author Manuscript

To evaluate significant differences, we set the voxel threshold at P < 0.001 (uncorrected)
over whole-brain with an extent threshold empirically chosen to be more than 2-3 times of
the expected voxels per cluster estimated in each SPM run and searched for clusters that
survived at family-wide error (FWE)-corrected P < 0.05. Significant regions were localized
by Talairach Daemon software (Research Imaging Center, University of Texas Health
Science Center, San Antonio, TX) after applying an MNI-to-Talairach conversion. SPM
maps of t-statistic were overlaid on a standard T1-weighted MRI brain template in
stereotaxic space. To quantify metabolic changes in specific regions, we constructed a 4-mm
radius spherical volume of interest (VOI) in the image space, centered at the peak voxel of
clusters that were significant in each SPM analysis. We then calculated the relative cerebral
glucose metabolic values (i.e., globally normalized) in patients and normal controls with
ScanVP software.
Statistical Analysis

Author Manuscript

Differences in PSPRP scores between patients and normal controls were assessed using twosample t-tests in the derivation cohort of each pattern. Changes in PSPRP score over
multiple groups in one cohort or between the cohorts were evaluated using one-way analysis
of variance (ANOVA) with differences between groups examined post-hoc with Bonferroni
tests. Discrimination power was determined by receiver operating characteristic (ROC)
analysis. Relationships between PSPRP scores and clinical measures in patients or between
two PSPRP scores in the same groups were determined by computing Pearson correlation
coefficients. Group differences in regional metabolic values were assessed using two-sample
t-tests in a single cohort and one-way ANOVA across the two cohorts. All analyses used
SPSS software (SPSS Inc., Chicago, IL) and were considered significant for P < 0.05.
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Results
Metabolic Brain Network in the Combined Cohort
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Pattern identification and disease discrimination—Spatial covariance analysis of
PET scans in the PSP and healthy subjects from the USA and China examined the
first 5 PCs that accounted for 54.5% of subject × voxel variance. A PSPRP was selected
from a linear combination of PC1, PC2, PC3 and PC5 [16.8% variance accounted for (VAF)]
whose expression yielded the lowest AIC value for group separation in the logistic
regression model. This pattern was characterized bilaterally by relative metabolic decreases
in the middle prefrontal/cingulate and ventrolateral prefrontal cortices, striatum, thalamus
and midbrain, associated with metabolic increases in the hippocampus or parahippocampus,
insula and parieto-temporal cortices (Fig 1A) and reliable (Fig 1B; P < 0.001, bootstrap
estimation: 1000 iterations). Subject scores of PSPRP measured in all subjects in this
combined cohort showed an effect of group (ANOVA: F[3,96] = 138.1, P < 0.0001; Fig 1C)
with elevation in the PSP/MSA patients (P < 0.0001, post-hoc tests) but not in the PD
patients (P = 0.18) compared to the normal (NL) groups. Network scores were also greater
in the PSP patients (P < 0.0001) than in the MSA patients and correlated with disease
duration in the PSP patients (r = 0.49, P = 0.028) but not in the MSA or PD patients (|r| ≤
0.21, P ≥ 0.22). Network scores did not correlate with the unified Parkinson’s disease rating
scale (UPDRS) motor ratings in any patient groups (P ≥ 0.22). PSPRP scores exhibited
increased accuracy in discrimination of the PSP patients from the MSA, PD and NL groups
(area under the curve [AUC] ≥ 0.928 ± 0.049) and the MSA patients from the PD and NL
groups (AUC ≥ 0.938 ± 0.031) according to the ROC analysis (Fig 1D; Supplementary Table
I). Furthermore, PSPRP scores did not differ (P ≥ 0.17) between the two cohorts in the NL,
PSP and MSA subjects but were greater (P < 0.01) in the American patients with PD.
18F-FDG

Author Manuscript

Disease discrimination by pattern expression in early stage patients—There
was also an effect of groups in PSPRP scores in Cohort 2 with parkinsonian patients at early
stages (ANOVA: F[3,64] = 48.1, P < 0.0001; Fig 2A); Network scores were elevated in the
PSP patients (P < 0.0001, post-hoc tests) compared to the NL, MSA and PD subjects but did
not differ among the latter three groups (P = 1.0). Likewise, the ROC analysis disclosed
increasing accuracy for discriminating the PSP patients from the MSA, PD and NL groups
(AUC ≥ 0.964 ± 0.030; Fig 2B; Supplementary Table II).

Author Manuscript

Differences in relative regional metabolism—SPM analysis of 18F-FDG PET scans
from the USA and China revealed bilaterally distributed abnormal metabolism in the PSP
patients compared to the healthy subjects. Relative regional metabolism decreased in the
middle prefrontal/cingulate and ventrolateral prefrontal cortices, striatum, thalamus and
midbrain, but increased in the hippocampus/parahippocampus, insula, cerebellum and
parieto-temporal regions (Fig 3A; Table III. P < 0.001; none survived at FWE-corrected P <
0.05). This was also seen by relative metabolism measured post-hoc in several primary
regions showing reductions in the frontal lobe, striatum and thalamus but increases in the
parahippocampus and paracentral gyrus in the patients relative to the controls (P < 0.001;
Fig 3B-G).
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Comparison of topographic patterns and disease discrimination—Analogous
analysis in the American or Chinese cohort interrogated the first 4 PCs accounting for 58.9%
or 53.5% of subject × voxel variance. A PSPRP was selected by a linear combination of PC1
and PC4 (29.5% VAF) or PC1, PC2 and PC3 (29.0% VAF). Both PSP-related patterns
showed highly similar topographies (Fig 4A; Fig 5A; c.f., Fig 1A) with their regional
weights correlating strongly on voxel-based analysis within the brain (r = 0.932, P <
0.0001). PSPRP scores revealed an effect of group among all subjects in the American or
Chinese cohort (ANOVA: F[3,46] = 59.2/79.8, P = 0.0001; Supplementary Fig 1). Network
scores of each PSPRP were abnormally elevated in the PSP (P < 0.0001) and MSA (P =
0.038/0.003) patients, and also variably in in the PD patients (USA: P = 0.362; China: P <
0.001) compared to the normal controls. These scores were also greater in the PSP patients
(P < 0.0001) than those in the MSA patients.

Author Manuscript

Comparison of pattern expression—Subject scores of both PSPRPs for the four
relevant groups are provided in Table IV. ANOVA revealed an effect of group for the
expressions of PSPRP in the American cohort and those in the Chinese cohort (F[3,36] =
56.8, P < 0.0001; Fig 4B) or vice versa (F[3,36] = 75.6, P < 0.0001; Fig 5B). PSPRP scores
increased in the PSP patients relative to the healthy controls in both cohorts (P < 0.0001,
post-hoc tests), were similar between the two normal groups (P = 1.0) but differed between
the two PSP groups (P = 0.06/0.007). Subject scores in American patients and controls for
the identification of PSPRP in the USA and the validation of PSPRP in China correlated
highly (both groups: r = 0.984, P < 0.001; controls: r = 0.906, P < 0.001; PSP: r = 0.938, P <
0.001; Fig 4C). Likewise, Chinese subject scores for the identification of PSPRP in China
and the validation of PSPRP in the USA also correlated (both groups: r = 0.964, P < 0.001;
controls: r = 0.707, P < 0.02; PSP: r = 0.799, P < 0.005; Fig 5C).

Author Manuscript

Comparison of relative regional metabolism—Conjunction analysis localized a large
number of bilaterally overlapping brain regions of abnormal metabolism between the
American and Chinese cohorts. In comparison with healthy controls, PSP patients showed
decreased metabolism in the middle prefrontal/cingulate and ventrolateral prefrontal
cortices, striatum, thalamus and midbrain, and increased metabolism in hippocampus/
parahippocampus, cerebellum and parieto-temporo-occipital regions (Fig 6A; Table V; P <
0.001, with some regions survived at FWE-corrected P < 0.05). This was further seen by
relative metabolism measured post-hoc in several primary regions showing an effect of
group (ANOVA: F[3,36] ≥ 12.85, P < 0.0001; Table IV) and decreases in the frontal lobe,
striatum and thalamus, but increases in the parahippocampus and paracentral gyrus in the
patients relative to the controls across both cohorts (post-hoc tests: P < 0.001; Fig 6B-G); no
differences were evident between the control (P ≥ 0.23) or patient (P ≥ 0.20) groups.
Interaction analysis revealed greater PSP-related metabolic increases in the occipital gyrus/
cuneus in the American cohort compared to the Chinese cohort (Fig 7A; P < 0.001
uncorrected and not survived at FWE-corrected P < 0.05). The post-hoc analysis disclosed
an effect of group (ANOVA: F[3,36] = 5.99, P = 0.002; Table IV) with increased cuneus
metabolism in the American cohort but non-significant decline in the Chinese cohort
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comparing PSP patients to normal controls (Fig 7B). Comparing the Chinese cohort to the
American cohort, cuneus metabolism was higher (P = 0.018) in the controls but decreased
not significantly (P = 0.436) in the PSP patients. More hyperactive regions that differ in
abnormal metabolism between both cohorts were detected in anterior cingulate and superior
temporal gyrus at a lower threshold (Supplementary Table III; P < 0.01).

Author Manuscript

Group differences in relative regional metabolism in each cohort—For the
American or Chinese cohort, compared to healthy subjects, PSP patients exhibited metabolic
decreases or increases bilaterally in the same regions as revealed in the conjunction analysis
described above (Supplementary Tables IV-V; Supplementary Figs 2–3 A). Increased
metabolism was more pronounced in the occipital gyrus in the American cohort but in the
cerebellar tonsil in the Chinese cohort. Relative metabolism decreased in the frontal lobe,
putamen and thalamus but increased in the temporal lobe including parahippocampus in the
PSP patients versus the healthy controls (post-hoc: P < 0.001; Supplementary Figs 2-3 B).

Discussion

Author Manuscript

This study reports abnormal cerebral metabolic characteristics in PSP that are highly
reproducible across patient populations and tomographs with both multivariate and
univariate analytical approaches. Firstly, we used spatial covariance analysis of 18F-FDG
PET images to identify specific metabolic networks associated with PSP in the American
and Chinese cohorts in combination or singly. This resulted in a highly reliable PSPRP in
the combined sample of PSP and healthy subjects and its expression discriminated between
the healthy controls, PSP, MSA and PD patients. We observed a high level of similarities
between the two site-specific patterns in terms of the topography and network expression.
Indeed, the PSPRP from China accounted for ~86% of the variation in the region weights for
the PSPRP from the USA. The separate analysis in each cohort replicated the differential
diagnosis among all subject groups seen in the combined cohort. Both metabolic networks
were also comparable by a cross validation with subject scores in prospective cohorts of PSP
patients and healthy subjects. This was in accord with a previous study that reported
reproducible network expression in multiple American patient groups scanned on the same
PET camera (Eckert et al., 2008). Secondly, we localized analogous differences in regional
metabolic activity in the same groups of PSP patients and healthy subjects on a whole brain
basis with SPM analysis. We found that PSP patients from the two cohorts shared a large
number of overlapping areas with abnormal metabolism in both cortical and subcortical
regions. Post-hoc VOI analyses of relative metabolic values further confirmed the significant
differences in these brain regions between the patient and control groups.

Author Manuscript

We need to emphasize that this work represented the first cross-validation study to
investigate reproducible metabolic abnormalities between truly independent cohorts of
patients with PSP using two different analytical approaches. The spatial covariance analysis
was aimed to derive a brain network with variance information in glucose metabolism in
18F-FDG PET images from PSP patients and controls. By contrast, the SPM analysis was
designed to capture regionally-specific differences in mean glucose metabolism between
patients and controls. They actually portrayed different but complementary measures of
brain dysfunction. Therefore, the application of network and regional analyses used in this
Hum Brain Mapp. Author manuscript; available in PMC 2019 July 01.
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study is helpful in describing the pathophysiology of PSP at both the systems and local
levels and may provide more valuable imaging biomarkers for the disease.
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The current work demonstrated topographical similarities between the resulting patterns at
the systems and local levels in both cohorts (together or individually), in agreement with
previous reports in another independent cohort in the Netherlands (Teune et al., 2010; Teune
et al., 2013). Comparable distributions of abnormal regional metabolism between both
cohorts in this study were responsible for the similarly elevated network scores of the two
PSPRPs, given that subject score is a similarity measure between the topography of a
covariance pattern and the metabolic distribution of a particular image. The high degree of
comparability in the PSPRPs between the Chinese and American medical centers reported
here is analogous to that for the Parkinson’s disease-related patterns (i.e., PDRPs) from the
same two centers (Wu et al., 2013). Our work is part of an international collaborative effort
to cross-validate the reproducibility of all PD-related network biomarkers. Indeed, the
expression of metabolic brain networks in multiple forms of parkinsonism has proven to be
viable biomarkers for early differential diagnosis based on a series of rigorous multi-center
validation studies performed prospectively in individual parkinsonian patients (Ko et al.,
2017; Niethammer et al., 2014; Tang et al., 2010; Tripathi et al., 2016).

Author Manuscript
Author Manuscript

Using both analytical approaches noted above, we observed metabolic decreases in the
middle prefrontal/cingulate and ventrolateral prefrontal cortices, striatum, thalamus and
midbrain in both cohorts of PSP patients. These findings were compatible with previous
imaging studies that described reduced cerebral blood flow or metabolism in patients with
PSP (Eckert et al., 2005; Eckert et al., 2008; Kimura et al., 2011; Klein et al., 2005;
Kobayashi et al., 2013; Stamelou et al., 2009; Teune et al., 2010; Teune et al., 2013).
Furthermore, the loss of neurons in relevant regions verified by autopsy studies in PSP
patients also provided support to our results (Pahapill and Lozano, 2000; Zweig et al., 1987).
The decreased metabolism in these cerebral regions is thought to be correlates of
dysfunction in a supraspinal locomotor network (SLN). This network, including both
indirect and direct pathways, is considered to be responsible for gait control in human beings
(Bohnen and Jahn, 2013; Zwergal et al., 2013). Indeed, the indirect pathway of SLN runs
from the frontal cortex via the basal ganglia to the brainstem locomotor centers, allowing for
the modulation of gait pattern in response to external demands. By contrast, the direct
pathway of SLN goes from the motor cortex to the spinal cord, bypassing the brainstem
centers and playing a more important role during undisturbed locomotion. The normal
function of the indirect pathway in SLN is largely disturbed in PSP by decreased regional
metabolism. Although the direct pathway subsequently overprojects as an early
compensatory mechanism, it cannot adequately adapt to environmental demands, causing
gait impairment (e.g., akinesia and freezing of gait) in the PSP patients. This assumption is
further supported by increased metabolic activity in the cortices surrounding paracentral
lobule (including mainly primary motor cortex and supplementary motor area) as observed
in the present study, likely reflecting compensation for the direct pathway in SLN.
All PSP patients in this study exhibited upward or downward vertical gaze palsy, a feature
with high specificity for differentiating PSP from other parkinsonian syndromes, as was also
evident in the discrimination outcome by PSPRP network activity. In accordance with this
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clinical symptom and network association, we observed a decrease in metabolism in the
medial frontal cortex, the area responsible for the control of eye movements in healthy
volunteers (Hanakawa et al., 2008; Paus et al., 1993). This is compatible with prior imaging
studies reporting significant correlation of vertical gaze palsy with decreased metabolism in
the same area (Amtage et al., 2014). Given that the frontal cortex is involved with normal
function of executive tasks, the early onset of cognitive impairment in PSP may also be
related to hypometabolism in this region (Kim et al., 2014; Lee et al., 2016). Pseudobulbar
palsy such as dysphagia and dysarthria is another supportive criterion for clinical diagnosis
of PSP. This condition is usually caused by damage to the neurons of the brainstem,
specifically to the corticobulbar tract. In this vein, we may attribute the decreased
metabolism of midbrain observed in this study as an indication of pseudobulbar palsy in
PSP. Nevertheless, more studies are needed to provide clearer evidence on this correlation.

Author Manuscript
Author Manuscript

This study also revealed increased metabolism in the territories of hippocampus or
parahippocampus and temporal cortex in both cohorts of patients with PSP. While abnormal
metabolism in hippocampus/parahippocampus was reported in PSP patients (Teune et al.,
2010), altered structures in these regions were also noted previously in several anatomical
MRI studies (Agosta et al., 2010; Messina et al., 2011; Padovani et al., 2006; Saini et al.,
2013). The reasons for such abnormalities still remain unclear, but in all likelihood result
from activations by specific circuits in the basal ganglia (Albin et al., 1989) and may be
related with early cognitive impairment in PSP patients. Hypermetabolism in temporal lobe
has also been described in prior functional imaging studies (Teune et al., 2010), and it is
plausible that increased metabolism in this region may reflect elevated sensory control in
patients with PSP. We also replicated the previous finding of increased regional metabolism
in the insula, middle occipital gyrus and cerebellum (Teune et al., 2010). While there is a
possible link between cerebellar abnormality and impaired balance capacity in PSP patients,
metabolic changes in insula and occipital gyrus may be explained by deficient hand-eye
motor movement and mild cognitive dysfunction in patients (Anderson et al., 1994).

Author Manuscript

The imaging results reported in this study are generally compatible with demographic and
clinical features of subject groups that are closely matched between the American and
Chinese cohorts (Table I). The distribution of these features among different groups is highly
representative of sample populations encountered in clinical practice, particularly in the
combined cohort. Hence, we used the combined American and Chinese sample to define and
characterize the topography of PSPRP and assess the diagnostic performance and clinical
correlation with network scores (cf., Fig 1). Comparing the American and Chinese cohorts,
PSPRP scores did not differ in the PSP or MSA groups consistent with their similar clinical
characteristics; PSPRP scores were higher in the PD group in the American cohort in line
with longer disease duration. We further found that without any clinical correlations in the
MSA and PD patients, PSPRP scores correlated with disease duration but not UPDRS motor
ratings in the PSP patients, even with the use of both early and advanced parkinsonian
patients included in this study. The latter could be due to the small sample size in our
patients or the use of a clinical rating scale that is not specific to complexity underlying the
symptomatology of PSP. Despite age/gender differences in some healthy and patient groups
between the different cohorts (Tables I–II), PSPRP scores did not show any differences or
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correlations with respect to these variables suggesting that age/gender do not play a big role
in PSP-related network analysis and have no effect on performance in differential diagnosis.

Author Manuscript

The patients recruited for the primary analyses in this study were all clinically-confirmed
with at least one-year follow-up at the time of 18F-FDG PET imaging. Most patients referred
to scanning in clinical routine are more likely to be suspected of having parkinsonism at
earlier stages. To this end we found that PSPRP activity can still discriminate PSP from
other groups in the second cohort of patients with early, clinically unclassifiable
parkinsonism (Fig 2). PSPRP scores were lower in each of these patient groups than those in
the combined American and Chinese cohort (see Supplementary Fig 4). It is expected that
diagnostic performance of quantitative metabolic network activity reported in the current
study can be further improved in realistic clinical practice with the use of the novel
classification algorithm including metabolic brain networks in other forms of parkinsonism
(Tang et al., 2010; Tripathi et al., 2016).
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Over the last few decades, high resolution MRI scanners combined with advanced
quantitative techniques have contributed significantly to measurements of structural and
functional changes for the discrimination of PSP from other forms of parkinsonism (Boxer
et al., 2017; Whitwell et al., 2017). Currently, magnetic resonance parkinsonism index
(MRPI) appears to be one of the most mature MRI biomarkers for assessing subcortical
atrophy of PSP, which was defined by multiplying the area ratio of pons to midbrain by the
width ratio of middle to superior cerebellar peduncles. It has been recently reported that
MRPI could yield very high sensitivity of 100% and specificity of 99.2-100% for PSP
(Nigro et al., 2017) and was also able to predict development of the disease (Whitwell et al.,
2017). In response to the great progress in MRI we have initiated a research project to
develop and cross-validate PET- and MRI-based brain network biomarkers in parkinsonism
using modern multimodality neuroimaging techniques. By computing PSPRP activity in a
large cohort with both FDG PET and perfusion MRI scans we found that network scores
from metabolic images are superior compared to blood flow images in accurately
differentiating between healthy subjects and moderate-stage patients with PSP, MSA and PD
from the preliminary results (Supplementary Table VI; Supplementary Fig 5). A direct
comparison of diagnostic performance between PSPRP activity and MRPI in these patient
populations with FDG PET and perfusion/structural MRI) would be warranted given the
involvement of brainstem as a common key node in both biomarkers that may help elucidate
the unique relationships between metabolic and pathologic substrates underlying the
pathogenesis of PSP.

Author Manuscript

Despite the high degrees of similarity across the two cohorts there remain some inherent
discrepancies as a result of inevitable differences in subject characteristics, scanner designs
and imaging protocols. We further note that the Chinese PSP patients had more severe
symptoms and longer duration than their American counterparts though not significantly
different. Albeit not prominent, some differences in PSP-related metabolic characteristics
across the patient populations and scanners were reported in this study regardless which
analytic approach was used. Indeed, network activity of PSPRP in China was greater but
more variable in the Chinese patients than in the American patients, and had lower degrees
of correlations per subject group than PSPRP in the USA. Furthermore, metabolic increases
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were observed in the cerebellum mainly in the Chinese patients with PSP but in the occipital
regions predominately in the American patients. We also found that cuneus metabolism in
PSP patients was decreased in the Chinese cohort but elevated in the American cohort. The
noisier and variable data in the Chinese cohort may be attributed to the PET/CT scanner
known to have higher variability than the dedicated PET camera, owe to the use of different
attenuation correction methods (CT vs. PET transmission scanning) and reconstruction
algorithms (iterative vs. analytical) in the creation of PET emission images. Nonetheless, as
these disease-related metabolic characteristics are highly reproducible in major cerebral
regions of PSP patients on a whole brain basis and PSPRP activity can accurately
differentiate PSP from other forms of parkinsonism, it strongly suggested that such a pattern
is well-qualified to offer a specific and reliable imaging marker for clinical diagnosis of PSP.

Author Manuscript
Author Manuscript

Several limitations should be noted in this study: (1) in the absence of neuropathological
confirmation of PSP in our patient cohorts we relied on the clinical diagnostic accuracy of
movement disorders experts at each site. This was a valuable strategy reflecting how PSP is
diagnosed in the real-world; (2) the sample sizes of PSP patients and healthy controls were
relatively small at both sites so as to conform to the PSP-related metabolic pattern already
established in the USA. These limited samples might be justifiable given the more severe
metabolic abnormalities inherent in this rapidly degenerative disease. This issue was mostly
mitigated by combining all PET images from the two sites in a series of primary analysis
reported in this article. The fact that analogous metabolic patterns were identified across two
independent cohorts suggest that the clinical diagnosis were accurate and the sample sizes
were adequate in this study; (3) the relationship of brain glucose metabolism to clinical
measures of disease severity and cognitive dysfunction has not been fully demonstrated due
to the limited samples, and despite the observed correlation of network activity with PSP
duration; (4) the present study did not exclusively classify patients with subtypes of PSP.
Our PSP patients had predominately Richardson’s syndrome based on primary clinical
features present at follow-up. It will be still necessary to replicate the results reported here in
different PSP variants and to identify corresponding clinical correlates with larger sample
sizes.

Conclusion

Author Manuscript

In this study, we revealed similar topographies in the spatial covariance brain network and
distribution of abnormal regional glucose metabolism in PSP by combining 18F-FDG PET
data of healthy subjects and patients from American and Chinese medical centers. The
results of cross-validation between the two centers confirm the presence of highly
reproducible PSP-related metabolic brain networks and regional activity patterns across
different patient populations and imaging instrumentation. We also showed that PSP-related
brain network is reliable on a voxel basis and its expression in individual subjects can
discriminate PSP patients from healthy controls as well as from other parkinsonian patients
in independent cohorts at both early and advanced clinical stages of parkinsonism. Network
measure from 18F-FDG PET imaging may serve as a reliable and objective marker of PSP in
clinical practice and potential research trials. Metabolic brain network generated in a large
cohort of healthy controls and pathologically-confirmed patients from a single site or
multiple centers can further validate PSPRP going forward.
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Fig 1. PSP-related pattern (PSPRP) identified by spatial covariance analysis of 18F-FDG PET
scans from PSP patients and healthy controls in both American and Chinese cohorts

A. This pattern was characterized by decreased (blue) metabolic activity in the bilateral
middle prefrontal cortex (PFC)/cingulate, ventrolateral prefrontal cortex (VLPFC), striatum,
thalamus and midbrain, covarying with increased (red) metabolic activity in the
hippocampus/parahippocampus and parieto-temporal cortices. The overlays are depicted in
neurological orientation. The thresholds of the color bars represent Z-values. B. The
topography of PSPRP was reliable as estimated by a voxelwise bootstrapping algorithm in
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conjunction with spatial covariance analysis in the combined cohort. The displays represent
the maps of inverse coefficient of variation (ICV) thesholded at P < 0.001 following 1000
iterations over the whole brain. C. The expression of PSPRP discriminated the PSP patients
from the healthy controls (i.e., NL) as well as from the MSA and PD patients (P < 0.0001;
post-hoc tests). Network scores were also elevated in the MSA patients compared with the
healthy controls and PD patients, but much lower than those in the PSP patients (P <
0.0001). The error bars represent standard deviations. D. Receiver operating characteristic
(ROC) analysis revealed different levels of group discrimination by subject scores of PSPRP.
The graph displays the fitted ROC curves for improved visualization.
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Fig 2. Differential diagnosis by subject scores of PSPRP in an independent Chinese cohort of
healthy controls and parkinsonian patients at early stages

A. The expression of PSPRP discriminated the PSP patients from the healthy controls (i.e.,
NL) as well as from the MSA and PD patients (P < 0.0001; post-hoc tests). There were no
differences in network scores between the MSA and PD patients or compared with the
healthy controls. B. Receiver operating characteristic (ROC) analysis revealed different
levels of group discrimination by subject scores of PSPRP. The graph displayed the fitted
ROC curves for improved visualization. The error bars represented standard deviations.
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Fig 3. Brain regions with significant metabolic differences in PSP patients compared with
healthy controls detected by SPM analysis of 18F-FDG PET scans in both American and Chinese
cohorts

A. Normalized glucose metabolism in the PSP patients decreased (blue) in the middle
prefrontal cortex (PFC)/cingulate, ventrolateral prefrontal cortex, striatum, thalamus and
midbrain, but increased (red) in the hippocampus/parahippocampus and parieto-temporal
regions compared to normal (NL) subjects (P < 0.001). The overlays are depicted in
neurological orientation. The thresholds of the color bars represent T-values. B-G. Group
differences in relative metabolic values in select cortical and subcortical regions, obtained
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post-hoc in spherical volumes of interest (4 mm radius) centered at the peak coordinates of
clusters deemed significant from the prior SPM analysis on a voxel-by-voxel basis. The
metabolic values in the healthy controls or the PSP patients were separated into different
sites so as to visualize their reproducibility across both cohorts. The error bars represent
standard deviations.
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Fig 4. PSP-related pattern (PSPRP) identified by spatial covariance analysis of 18F-FDG PET
scans from PSP patients and healthy controls in the American cohort

A. This pattern was characterized bilaterally by decreased (blue) metabolic activity in the
middle prefrontal cortex (PFC)/cingulate, ventrolateral prefrontal cortex (VLPFC), striatum,
thalamus and midbrain, along with increased (red) metabolic activity in the hippocampus/
parahippocampus and parieto-temporal cortices. The overlays are depicted in neurological
orientation. The thresholds of the color bars represent Z-values. B. The expression of PSPRP
discriminated the PSP patients from the healthy controls (i.e. NL) in both American and
Chinese cohorts (P < 0.0001; post-hoc tests). The error bars represent standard deviations.
C. Individual scores in the same cohort correlated highly across both healthy controls and
PSP patients used for the identification of PSPRP in the USA and for the validation of
PSPRP in China.
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Fig 5. PSP-related pattern (PSPRP) identified by spatial covariance analysis of 18F-FDG PET
scans from PSP patients and healthy controls in the Chinese cohort

A. This pattern was characterized bilaterally by decreased (blue) metabolic activity in the
middle prefrontal cortex (PFC)/cingulate, ventrolateral prefrontal cortex (VLPFC), striatum,
thalamus and midbrain, associated with increased (red) metabolic activity in the
hippocampus/parahippocampus and parieto-temporal cortices. The overlays are depicted in
neurological orientation. The thresholds of the color bars represent Z-values. B. The
expression of PSPRP discriminated the PSP patients from the healthy controls (i.e., NL) in
both American and Chinese cohorts (P < 0.0001; post-hoc tests). The error bars represent
standard deviations. C. Individual scores in the same cohort correlated highly across both
healthy controls and PSP patients used for the identification of PSPRP in China and for the
validation of PSPRP in the USA.
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Fig 6. Brain regions with similar abnormal metabolism in PSP patients relative to healthy
controls detected by conjunction analysis of 18F-FDG PET scans with SPM across the American
and Chinese cohorts

A. Metabolism in the PSP patients decreased (blue) in the middle prefrontal cortex (PFC)/
cingulate, ventrolateral prefrontal cortex (VLPFC), striatum, thalamus and midbrain, but
increased (red) in the hippocampus as well as parieto-temporal regions compared to normal
(NL) subjects (P < 0.001). The thresholds of the color bars represent T-values. B-G. Group
differences in relative metabolic values in select cortical and subcortical regions, obtained
post-hoc in spherical volumes of interest (4 mm radius) centered at the peak coordinates of
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clusters deemed significant from the prior SPM analysis on a voxel-by-voxel basis. The error
bars represent standard deviations.
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Fig 7. Brain regions with different abnormal metabolism in PSP patients relative to healthy
controls detected by interaction analysis of 18F-FDG PET scans with SPM across the American
and Chinese cohorts

A. Metabolism in the PSP patients increased (red) in the middle occipital gyrus/cuneus
versus normal subjects (NL) in the American cohort (P < 0.001) compared to the group
difference in the Chinese cohort. The thresholds of the color bars represent T-values. B.
Group differences in relative metabolic values in this region, obtained post-hoc in spherical
volumes of interest (4 mm radius) centered at the peak coordinates of clusters deemed
significant from the prior SPM analysis on a voxel-by-voxel basis. The error bars represent
standard deviations.
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